Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease
Explore this paper's citation graph
Summary
The remaining unmet needs (and hence opportunities for new biomarkers) in two major clinical areas: early diagnosis of acute myocardial infarction; and early diagnosis and management of acute heart failure are discussed.
- Type
- article
- Published
- 2015-03-20
- Cited by
- 7
- References
- 81
- OpenAlex
- https://openalex.org/W25676700
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5402654
Keywords
Art
References
- Biomarkers in heart failure.
- Soluble Concentrations of the Interleukin Receptor Family Member ST2 and &bgr;-Blocker Therapy in Chronic Heart Failure
- Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
- Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
- Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein.
- Copeptin: a biomarker of cardiovascular and renal function.
- Autoantibodies against apolipoprotein A‐1 and phosphorylcholine for diagnosis of non‐ST‐segment elevation myocardial infarction
- The universal definition of myocardial infarction
- Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
- Interleukin family member ST2 and mortality in acute dyspnoea
- Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
- Vasopressin antagonism in heart failure.
- Copeptin: clinical use of a new biomarker.
- Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department.
- Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men.
- Benchmarks for the Assessment of Novel Cardiovascular Biomarkers
- Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction.
- How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study.
- Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995.
- Comparison of heart-type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myocardial infarction.
Cited by
- S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers
- Performance Evaluation of Cardiac Troponin I Assay: A Comparison Between the Point-of-care Testing Radiometer AQT90 FLEX and the Central Laboratory Siemens Advia Centaur Analyzer
- Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease
- The Biomarkers for Acute Myocardial Infarction and Heart Failure
- Characterization of inflammatory profile by breath analysis in chronic coronary syndromes.
- Differential gene expression patterns in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction
- Assessment of copeptin and obestatin levels in coronary artery disease patients
Related papers
No related papers recorded.